Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
- Cambridge University NHS Hospitals Foundation Trust, United Kingdom
- Clinical Microbiology & Public Health Laboratory, Public Health England, United Kingdom
- Medical Research Council Biostatistics Unit, University of Cambridge, United Kingdom
- Statistical Laboratory, Centre for Mathematical Sciences, University of Cambridge, United Kingdom
- Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, United Kingdom
- Department of Medicine, University of Cambridge, United Kingdom
- Occupational Health and Wellbeing, Cambridge Biomedical Campus, United Kingdom
- Division of Virology, Department of Pathology, University of Cambridge, United Kingdom
- Cambridge COVID-19 Testing Centre and AstraZeneca, Anne McLaren Building, United Kingdom
- NHS Blood and Transplant, United Kingdom
- Cambridge Institute for Medical Research, University of Cambridge, United Kingdom
Figures
Figure 1
Proportion of positive screening tests for SARS-CoV-2 amongst HCWs from the CUHNHFT asymptomatic screening programme (grey bars; week 1, 18–24 January 2021; week 2, 25–31 January 2021) and Ct values of positive tests (Ct < 36; blue dots; both weeks).
RT-PCR targeting the SARS-CoV-2 ORF1ab genes was conducted at the Cambridge COVID-19 Testing Centre (part of the UK Lighthouse Labs Network). For proportions of positive screening tests, p-values for pair-wise comparisons of unvaccinated HCWs with HCWs <12 days or ≥12 days post-vaccination are shown (Fisher’s exact test; both weeks). For Ct values, medians ± interquartile ranges are shown.
-
Figure 1—source data 1
Proportions of positive asymptomatic SARS-CoV-2 screens and distributions of Ct values.
- https://cdn.elifesciences.org/articles/68808/elife-68808-fig1-data1-v2.xlsx
Tables
Table 1
Weekly numbers and proportions of positive SARS-CoV-2 test results spanning 6 weeks around the main study period (indicated in grey).
| Unvaccinated | <12 Days since vaccination | ≥12 Days since vaccination | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Week start | Total tests | Positive tests | % | Total tests | Positive tests | % | Total tests | Positive tests | % |
| 28 December 2020 | 2097 | 16 | 0.8% | 8 | 0 | 0.0% | 6 | 0 | 0.0% |
| 4 January 2021 | 4762 | 43 | 0.9% | 93 | 0 | 0.0% | 22 | 0 | 0.0% |
| 11 January 2021 | 3273 | 27 | 0.8% | 978 | 6 | 0.6% | 30 | 0 | 0.0% |
| 18 January 2021 | 2183 | 17 | 0.8% | 1716 | 8 | 0.5% | 483 | 1 | 0.2% |
| 25 January 2021 | 1069 | 9 | 0.8% | 1819 | 5 | 0.3% | 1506 | 3 | 0.2% |
| 1 February 2021 | 699 | 1 | 0.1% | 758 | 1 | 0.1% | 2825 | 1 | 0.0% |
Additional files
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
eLife 10:e68808.
https://doi.org/10.7554/eLife.68808
